Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis
This study highlights the unmet need for more effective PNH treatments to address the economic and clinical burden associated with PNH and improve disease control among patients.
Authors
- Soyon Lee (ORCID: https://orcid.org/0000-0002-2059-717X)
- Anumaxine Geevarghese
- Raj Desai
- Srinivas K. Tantravahi (ORCID: https://orcid.org/0000-0003-4899-3796)
- Shravanthi M. Seshasayee (ORCID: https://orcid.org/0000-0002-1692-7121)
- Glorian Yen (ORCID: https://orcid.org/0000-0002-3874-7789)
- Jincy Paulose
- Dominick Latrémouille-Viau (ORCID: https://orcid.org/0000-0002-8565-9220)
- Mohin Chanpura
- Annie Guérin
Institutions
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Novartis (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of health economics and outcomes research
- Published
- 2025-08-15
- DOI
- https://doi.org/10.36469/001c.142049
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharmaceuticals Corporation